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Introduction 
•  Current EASL guidelines consider a liver biopsy optional to diagnose 
severe alcoholic steatohepatitis (ASH). 
•  Based on clinical criteria (i.e. Maddrey-score / MDF ≥32) patients are 
initiated on corticosteroids (CS) (EASL guidelines 2012).  
•  In patients with acute decompensation of alcoholic cirrhosis, making a 
diagnosis of ASH on clinical grounds may be challenging, since it 
resembles acute-on-chronic liver failure (ACLF). 
•  We recently identified ductular bilirubinostasis (DB) as an early risk 
factor for ACLF1. 
Methods 
•  Prospective trial of 114 patients with alcoholic cirrhosis and suspicion 
of severe ASH (i.e. MDF ≥32) who underwent a transjugular liver biopsy 
within 3 days after admission.  
•  Literature-reported clinical, biochemical and histological parameters 
indicative of severe ASH and/or ACLF were assessed and correlated to 
the risk of death and the response to CS using logistic regression and 
survival analysis.  
Results I 
 
 
 
 
 
 
 
 
 
 
 
Results IV – Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results III – Ductular bilirubinostasis on early liver biopsy  
and correlation with infection, kidney failure and ALCF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results II – Clinical characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
• We confirmed that DB is an early marker of ACLF and independently predicts a poor outcome. 
• About one third of patients clinically suspected with severe ASH were misdiagnosed.  
• Especially patients with Maddrey ≥32 and histologically confirmed severe ASH and DB benefited from CS treatment. 
• This might explain the difference in response observed in trials assessing the value of CS for ASH. 
1Katoonizadeh et al. Gut 2010 
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P-value  
(between groups) 
Sex (m/f) 23/11 20/22 14/12 6/6 0.35 
Age (years) 52±2 50±2 54±2 54±2 0.54 
Alcohol intake (grams/day) 82±4 88±3 68±5 75±8 0.25 
HVPG (mm Hg) 18.3±1.4 19.0±1.0 18.3±1.3 16.5±0.75 0.77 
SIRS 62% (21/34) 48% (20/42) 65% (17/26) 58% (7/12) 0.46 
Infection at/during admission 65% (22/34) 43% (18/42) 65% (17/26) 42% (5/12) 0.12 
Plasma bilirubin at admission (mg/dl) 19.1±1.4 18.7±1.8 16.8±2.1 7.3±1.0 P<0.01 
MDF 60±5.0 56±3.7 51±4.0 46±3.2 0.31 
MELD 28.8±1.4 26.3±1.0 26.7±0.8 22.3 ± 1.2 0.02 
% CS-treated 53% (18/34) 69% (29/42) 27% (7/26) 17% (2/12) <0.0001 
Lille-score <0.45 (after CS) 44% (8/18) 72% (21/29) 43% (3/7) 50% (1/2) 0.21 
% Evolution towards ACLF** 88% (30/34) 56% (17/42) 81% (21/26) 75% (3/9) 0.03 
Median survival (days) 
CS treated vs. untreated 
81 vs. 38* >180  
(N.S.) 
95 vs. 55 
(N.S.) 
>180 
(N.S.) 
*P<0.05 
Overall 6-month survival 32% (11/34) 76% (32/42) 34% (9/26) 75% (9/12) <0.0001 
** EASL-CLIF criteria 
